HIV Drug Resistance EQA/PT Scheme

To assess the performance of laboratories in the detection of drug resistance mutations in the HIV-1 protease, reverse transcriptase, and integrase genes.

Total Number of Challenges: 1
Number of Panel Members: 4
Distribution / Testing Period: Q4
Sample NA Target Source Cultured and/or Clinical material
Matrix Panel Format Plasma
Panel Member Target Range Various mutations – protease (PR), reverse transcriptase (RT) and integrase (INT) genes
Panel Member Sample Volume 1.0 ml
Panel Sample Pre-treatment Requirement Ready for analysis. Treat as clinical samples and analyse accordingly.
Panel Analysis Type Sequence Analysis
Panel Testing Evaluated by various molecular methodologies
Storage / Shipment Conditions <-20°C / Frozen on Dry-ice
Accreditation / Regulatory Status Accredited to ISO 17043

$1,426.53